Healionics, Inc.
Seattle, US · Delaware corporation · 6 known investors
Healionics develops STARgraft, a synthetic vascular graft built on its STAR biomaterial scaffold that resists occlusion and infection to create a reliable bloodstream access site for kidney dialysis patients. The device has received FDA Breakthrough Device designation and targets the treatment of kidney failure through dialysis.
Founders & leadership
BR
Buddy RatnerFounder
MC
Mike ConnollyExecutive
AM
Andrew MarshallNamed on SEC filing
MM
Max MaginnessNamed on SEC filing
Board
RT
Ryan TakeuchiBoard director
AC
Arthur CouryBoard director
Investors · 6
Reported raises · per SEC filings
Form D private placements$18.2M disclosed across 4 rounds · 2018–2025
▶$2MraisedDec 2025 · 30 investors · OtherRule 506(b)
▶$2MraisedDec 2025 · 30 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Mike ConnollyExecutive Officer, Director
- Andrew MarshallDirector
- Ryan TakeuchiDirector
- Buddy RatnerDirector
- Arthur CouryDirector
- Offering amount
- $20M
- Amount sold
- $2M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedFeb 2024 · 70 investors · OtherRule 506(b)
▶$5.5MraisedFeb 2024 · 70 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Buddy RatnerDirector
- Arthur CouryDirector
- Mike ConnollyExecutive Officer, Director
- Ryan TakeuchiDirector
- Andrew MarshallDirector
- Offering amount
- $5.6M
- Amount sold
- $5.5M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.6MraisedDec 2020 · 86 investors · OtherRule 506(b)
▶$6.6MraisedDec 2020 · 86 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Andrew MarshallDirector
- Arthur CouryDirector
- Mike ConnollyExecutive Officer, Director
- Buddy RatnerDirector
- Ryan TakeuchiDirector
- Offering amount
- $10.2M
- Amount sold
- $6.6M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedJul 2019 · 72 investors · OtherRule 506(b)
▶$4.2MraisedJul 2019 · 72 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Buddy RatnerDirector
- Mike ConnollyExecutive Officer, Director
- Arthur CouryDirector
- Andrew MarshallDirector
- Max MaginnessExecutive Officer
- Ryan TakeuchiDirector
- Offering amount
- $5M
- Amount sold
- $4.2M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Cionic5 shared keywordsCionic develops the Neural Sleeve, an FDA-cleared wearable device that uses electrical muscle stimulation to improve walking and mobility for people with neurological conditions including Multiple Sclerosis, stroke, cerebral palsy, and spinal cord injury. The system combines hardware with an AI-powered app and personalized coaching to help users regain independence and confidence in daily activities.
Globus Medical4 shared keywordsGlobus Medical designs and manufactures spine, trauma, and robotic surgical products for the orthopedic medical device market. The company serves hospitals and surgical centers globally.
Solenic Medical4 shared keywordsSolenic Medical is a medical company; this page is an investor contact form and does not describe the company's products or technology in detail.
Companies competing with Healionics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $224.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $440.3K |
| Department of DefenseDefense Health Program | Phase II | 2016 | $999.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $224.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $206.5K |
| Department of DefenseDefense Health Program | Phase I | 2014 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $909.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $199.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2009 | $116.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Healionics, Inc. do?
- Healionics develops STARgraft, a synthetic vascular graft built on its STAR biomaterial scaffold that resists occlusion and infection to create a reliable bloodstream access site for kidney dialysis patients. The device has received FDA Breakthrough Device designation and targets the treatment of kidney failure through dialysis.
- Who founded Healionics, Inc.?
- Healionics, Inc. was founded by Buddy Ratner.
- Who are Healionics, Inc.'s investors?
- Healionics, Inc.'s investors include Alliance of Angels, Band of Angels, Central Texas Angel Network, iSelect Fund, Keiretsu Forum, NW Angel.
- How much funding has Healionics, Inc. raised?
- Healionics, Inc. has disclosed $18.2M raised across 4 rounds.
- Where is Healionics, Inc. headquartered?
- Healionics, Inc. is headquartered in Seattle, US.